Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 25 | 2021 | 11538 | 1.190 |
Why?
|
| Pleural Effusion | 1 | 2023 | 201 | 0.800 |
Why?
|
| Radiography, Thoracic | 4 | 2019 | 462 | 0.640 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 2173 | 0.630 |
Why?
|
| Thoracic Neoplasms | 3 | 2016 | 337 | 0.610 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2019 | 7551 | 0.600 |
Why?
|
| Diagnostic Errors | 3 | 2018 | 509 | 0.570 |
Why?
|
| Mediastinum | 5 | 2019 | 268 | 0.550 |
Why?
|
| Radiography | 2 | 2018 | 1904 | 0.550 |
Why?
|
| Diagnostic Imaging | 3 | 2017 | 1162 | 0.520 |
Why?
|
| Postoperative Complications | 5 | 2018 | 5542 | 0.520 |
Why?
|
| Smoking | 3 | 2014 | 2440 | 0.500 |
Why?
|
| Lung | 15 | 2018 | 3151 | 0.490 |
Why?
|
| Postoperative Care | 1 | 2017 | 739 | 0.460 |
Why?
|
| Pneumonectomy | 2 | 2018 | 831 | 0.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2020 | 5319 | 0.440 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1763 | 0.410 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 105 | 0.400 |
Why?
|
| Solitary Pulmonary Nodule | 3 | 2018 | 123 | 0.360 |
Why?
|
| Mass Screening | 2 | 2014 | 1509 | 0.340 |
Why?
|
| Multidetector Computed Tomography | 3 | 2017 | 150 | 0.280 |
Why?
|
| Immunotherapy | 4 | 2020 | 3341 | 0.260 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 13658 | 0.260 |
Why?
|
| Diagnosis, Differential | 8 | 2023 | 4744 | 0.260 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2021 | 406 | 0.250 |
Why?
|
| Mediastinal Neoplasms | 2 | 2018 | 423 | 0.230 |
Why?
|
| Ipilimumab | 2 | 2019 | 710 | 0.230 |
Why?
|
| Pleural Neoplasms | 2 | 2018 | 470 | 0.230 |
Why?
|
| Societies, Medical | 5 | 2020 | 1335 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 7702 | 0.220 |
Why?
|
| Humans | 44 | 2023 | 261506 | 0.210 |
Why?
|
| Radiosurgery | 3 | 2019 | 1330 | 0.190 |
Why?
|
| Benzimidazoles | 2 | 2021 | 428 | 0.190 |
Why?
|
| Radiologists | 1 | 2022 | 163 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3251 | 0.170 |
Why?
|
| Etoposide | 1 | 2021 | 870 | 0.170 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 406 | 0.170 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 1085 | 0.160 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 111 | 0.160 |
Why?
|
| Carboplatin | 1 | 2021 | 823 | 0.160 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2018 | 54 | 0.160 |
Why?
|
| Intensive Care Units | 2 | 2012 | 717 | 0.150 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 79 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2019 | 833 | 0.140 |
Why?
|
| Heart Neoplasms | 1 | 2018 | 214 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1249 | 0.140 |
Why?
|
| Fibrosis | 1 | 2019 | 793 | 0.140 |
Why?
|
| United States | 7 | 2020 | 15433 | 0.130 |
Why?
|
| Dyspnea | 1 | 2018 | 416 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 437 | 0.130 |
Why?
|
| Radiographic Image Enhancement | 2 | 2015 | 402 | 0.130 |
Why?
|
| Early Detection of Cancer | 4 | 2018 | 1258 | 0.130 |
Why?
|
| Taxes | 1 | 2014 | 7 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 698 | 0.130 |
Why?
|
| History, 16th Century | 1 | 2014 | 34 | 0.130 |
Why?
|
| History, 17th Century | 1 | 2014 | 40 | 0.130 |
Why?
|
| History, 18th Century | 1 | 2014 | 89 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2020 | 717 | 0.120 |
Why?
|
| Thoracic Wall | 1 | 2016 | 183 | 0.120 |
Why?
|
| History, 19th Century | 1 | 2014 | 154 | 0.120 |
Why?
|
| Smoking Prevention | 1 | 2014 | 138 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 7789 | 0.120 |
Why?
|
| Respiratory Tract Fistula | 1 | 2013 | 33 | 0.120 |
Why?
|
| Empyema | 1 | 2013 | 28 | 0.120 |
Why?
|
| Bronchial Fistula | 1 | 2013 | 37 | 0.120 |
Why?
|
| Multimodal Imaging | 2 | 2015 | 550 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2014 | 361 | 0.110 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 80 | 0.110 |
Why?
|
| Heart, Artificial | 1 | 2014 | 77 | 0.110 |
Why?
|
| Pleural Diseases | 1 | 2013 | 57 | 0.110 |
Why?
|
| Radon | 1 | 2012 | 11 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2014 | 441 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2015 | 246 | 0.110 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2012 | 21 | 0.110 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2013 | 59 | 0.100 |
Why?
|
| Intubation | 1 | 2012 | 40 | 0.100 |
Why?
|
| Thoracotomy | 1 | 2013 | 220 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 574 | 0.100 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2012 | 69 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 1946 | 0.100 |
Why?
|
| Prosthesis Implantation | 1 | 2014 | 263 | 0.100 |
Why?
|
| Chest Tubes | 1 | 2012 | 101 | 0.100 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2015 | 261 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 4557 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2014 | 598 | 0.100 |
Why?
|
| Occupational Exposure | 1 | 2012 | 244 | 0.090 |
Why?
|
| Air Pollutants | 1 | 2012 | 139 | 0.090 |
Why?
|
| Risk Factors | 3 | 2018 | 17523 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 1248 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 15862 | 0.090 |
Why?
|
| Tracheostomy | 1 | 2012 | 243 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 213 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2012 | 221 | 0.080 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 354 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2014 | 712 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1824 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 1225 | 0.080 |
Why?
|
| Phantoms, Imaging | 1 | 2014 | 1271 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2015 | 1411 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6009 | 0.080 |
Why?
|
| Sex Factors | 1 | 2012 | 2139 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14289 | 0.070 |
Why?
|
| Prevalence | 1 | 2014 | 3260 | 0.070 |
Why?
|
| Lymphoma | 1 | 2014 | 1467 | 0.070 |
Why?
|
| Middle Aged | 11 | 2021 | 86204 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 4971 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2021 | 2588 | 0.060 |
Why?
|
| Bevacizumab | 2 | 2018 | 938 | 0.060 |
Why?
|
| Acute Disease | 2 | 2019 | 2422 | 0.060 |
Why?
|
| Male | 12 | 2021 | 123000 | 0.060 |
Why?
|
| Adult | 9 | 2021 | 77950 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 8865 | 0.050 |
Why?
|
| Contrast Media | 2 | 2019 | 1472 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 29902 | 0.050 |
Why?
|
| Heart-Assist Devices | 1 | 2012 | 1171 | 0.050 |
Why?
|
| Aged | 8 | 2021 | 70117 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4757 | 0.050 |
Why?
|
| Female | 11 | 2021 | 141928 | 0.050 |
Why?
|
| Child | 1 | 2022 | 29154 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2021 | 32848 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 5112 | 0.050 |
Why?
|
| Heart Failure | 1 | 2014 | 2516 | 0.050 |
Why?
|
| Sclerosing Solutions | 1 | 2019 | 27 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2014 | 1014 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 4844 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 726 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 60 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2018 | 172 | 0.040 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2018 | 170 | 0.040 |
Why?
|
| Pleura | 1 | 2018 | 127 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 437 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 327 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 10035 | 0.040 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 237 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 665 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 388 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 604 | 0.040 |
Why?
|
| Prognosis | 3 | 2019 | 21713 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 588 | 0.030 |
Why?
|
| Radiology | 1 | 2019 | 434 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 607 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 15193 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1819 | 0.030 |
Why?
|
| Quinazolines | 1 | 2017 | 923 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2283 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2013 | 355 | 0.030 |
Why?
|
| Algorithms | 2 | 2014 | 3890 | 0.030 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 400 | 0.030 |
Why?
|
| Heart | 1 | 2018 | 1223 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 3443 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1033 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 2594 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2014 | 749 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 3101 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 21445 | 0.020 |
Why?
|
| Pyridines | 1 | 2017 | 1244 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 1823 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 3033 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2295 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2403 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4320 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 1586 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2017 | 1471 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 10331 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2018 | 2669 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9180 | 0.020 |
Why?
|
| Pneumonia | 1 | 2013 | 751 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7548 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 3343 | 0.020 |
Why?
|
| Liver | 1 | 2016 | 2961 | 0.020 |
Why?
|
| Critical Illness | 1 | 2012 | 714 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12221 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 12873 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 14889 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 3719 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 15179 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 37905 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 31252 | 0.010 |
Why?
|